Anaplastic Ependymoma Clinical Trials 2023

What are the top hospitals conducting anaplastic ependymoma research?

The search for effective treatments and improved outcomes in anaplastic ependymoma has led to a remarkable collaboration among leading hospitals across the United States. In New york, Memorial Sloan Kettering Cancer Center spearheads this effort with an impressive 25 ongoing clinical trials dedicated to anaplastic ependymoma, building on their extensive history of 24 completed trials since their first recorded study in 2009. On the opposite coast, Children's Hospital Los Angeles is making significant strides as well, currently conducting 20 active trials and having accomplished 23 previous studies since initiating their research journey back in 1997.

Meanwhile, Cincinnati Children's Hospital Medical Center holds a prominent position in the fight against anaplastic ependymoma with its commitment to ongoing clinical trials. With 18 active trials underway and a noteworthy tally of 27 previously conducted studies starting from their inaugural trial in 2003; it stands shoulder-to-shoulder with other esteemed institutions.

Children's Hospital Colorado also plays a vital role by actively exploring new avenues through its ongoing involvement in eighteen clinical trials related to anaplastic ependymoma. Having conducted twenty prior investigations since recording their first trial in2010; they have emerged as key contributors towards advancing our understanding of this condition.

In sunny Orlando, Arnold Palmer Hospital for Children does not fall behind either when it comes to contributing knowledge about this rare cancer subtype. With eighteen current clinical trials dedicated solely to anaplastic ependymoma and nineteen completed ones spanning over two decades since recording that historic moment backin2004; they are helping shape future treatment options for individuals affected by this challenging disease.

These top-tier medical centers located throughout the country symbolize both hope and progress within the realm of anaplastic ependymoma research. Their collective dedication exemplifies how collaboration can lead us closer to breakthroughs that hold promise for enhanced care strategies while raising optimism among patients worldwide

Which are the best cities for anaplastic ependymoma clinical trials?

When it comes to anaplastic ependymoma clinical trials, several cities in the United States offer a wealth of ongoing studies. New york City leads the way with 65 active trials exploring treatments like Pharmacological Study, Tazemetostat, Tipifarnib, and more. Orlando, Florida follows closely behind with 56 trials investigating interventions such as Pharmacological Study and 3-Dimensional Conformal Radiation Therapy. Saint Louis, Missouri also proves to be a prominent location for research with 53 active trials focusing on Pharmacological Study and Vemurafenib among others. These cities provide individuals diagnosed with anaplastic ependymoma access to cutting-edge clinical trials that contribute to advancements in treatment options and overall outcomes.

Which are the top treatments for anaplastic ependymoma being explored in clinical trials?

Exciting advancements are being made in the exploration of clinical trials for anaplastic ependymoma. Leading the charge is pembrolizumab, currently involved in four active trials dedicated to this specific type of cancer. Since its introduction in 2015, it has shown promise with one all-time trial focused on anaplastic ependymoma. Another notable treatment under investigation is a pharmacological study, making waves with three ongoing trials and a total of nine all-time studies since its inception in 2010. Additionally, ONC206 and brigatinib are emerging as potential game-changers, both participating in two active trials each and showing encouraging results thus far. As research progresses, these treatments hold immense hope for patients battling anaplastic ependymoma worldwide.

What are the most recent clinical trials for anaplastic ependymoma?

Recent clinical trials have brought hope to patients with anaplastic ependymoma, a rare and aggressive form of brain cancer. One promising study investigated the use of lorlatinib in combination with platinum and pemetrexed for treating this condition. Another trial focused on Arm A, which explored potential treatments for relapsed or refractory CNS tumors including anaplastic ependymoma. Furthermore, research has been conducted on LUTATHERA®, a targeted therapy using lutetium Lu 177 dotatate, as well as HER2 Specific CAR T Cell therapy and vudalimab. These trials mark significant advancements in our understanding of treatment options for anaplastic ependymoma, providing renewed optimism for patients and their loved ones during these challenging times.

What anaplastic ependymoma clinical trials were recently completed?

Recently completed clinical trials have made significant strides in advancing the treatment of anaplastic ependymoma. These trials represent promising developments in the field.